Studies related to Severity of Sickness and Zinc

Reduction In Duration Of Common Colds By Zinc Gluconate Lozenges In A Double-blind Study

Effect Decrease
Values Figure 2
Trial Design Randomized trial
Trial Length 1-7 Days
Number of Subjects 120
Sex Both Genders
Notes for this study:
In a randomized, double-blind, placebo-controlled trial, participants suffering from common colds were given zinc gluconate lozenges containing 23 mg of elemental zinc, initially two at once, and then one every 2 hours, not exceeding 12 for adults or 9 for youths, while children under 27 kg received half the dose, not exceeding 6 tablets daily. This persisted for 7 days. The analysis was restricted to the 65 participants who had reported being sick for 3 days or less before starting the trial and had continued taking their lozenges throughout the trial.

The zinc group saw a significantly faster rate of becoming asymptomatic, and at the end of 7 days. The prevalence of symptoms was significantly less in the zinc group. Symptom severity at every time point was also significantly lower in the zinc group.

There were notably more adverse events in the zinc group, with mouth irritation, distortion of taste, nausea, and complaints about the lozenges being unpalatable being noticeably greater in the zinc group.

Full details on all 9 studies are available to Examine Members. Try out the Examine Membership with a 14-day free trial.

Already a Member? Log in now to access.